Sage Therapeutics, Inc. announced the names of and certain information as of April 16, 2024, about the members of the board of directors who are not standing for re-election at 2024?s Annual Meeting are; Michael F. Cola, Chair of the Compensation Committee, Member of the Science and Technology Committee, Class and Year in Which Term Will Expire: Class III-2026, Director Since: 2014, Age: 64; James M. Frates, Chair of the Audit Committee, Member of the Compensation Committee, Class and Year in Which Term Will Expire: Class II-2025, Director Since: 2014, Age: 56; Jessica J. Federer, Member of the Audit Committee; Class and Year in Which Term Will Expire: Class III?2026, Director Since: 2023, Age: 41; George Golumbeski, Ph.D, Member of the Nominating and Corporate Governance Committee, Class and Year in Which Term Will Expire: Class II-2025, Director Since: 2019, Age: 66; Barry E. Greene, Chief Executive Officer, Class and Year in Which Term Will Expire: Class III-2026, Director Since: 2020, Age: 60; Jeffrey M. Jonas, M.D, Chair of the Science and Technology Committee, Class and Year in Which Term Will Expire: Class III-2026, Director Since: 2013, Age: 71. Michael F. Cola. Mr. Cola has served as a member of its Board of Directors since September 2014.

Mr. Cola has served as an advisor for Yale Ventures since October 2022 and an advisor for Mayo Ventures since June 2022. He served as Chief Executive Officer and a board member of Avalo Therapeutics, Inc. (formerly Cerecor, Inc.), or Avalo, a biopharmaceutical company, from February 2020 to February 2022. Prior to Avalo, Mr. Cola served as Chief Executive Officer of Aevi Genomic Medicine, Inc., or Aevi, a biopharmaceutical company formerly named Medgenics, Inc. from 2013 to February 2020.

Prior to joining Aevi, from 2005 to 2012, he served as president of specialty pharmaceuticals at Shire plc, or Shire, a global specialty pharmaceutical company. Previously, from 2000 to 2005, Mr. Cola served as a Growth Capital Provider and President of the life sciences group for Safeguard Scientifics, Inc., where he served as Chairman and Chief Executive Officer of Clarient, Inc., and Chairman of Laureate Pharma, Inc. In addition, Mr. Cola has held senior positions in product development and commercialization at Astra Merck Inc., where he led Phase 2 through Phase 4 clinical development efforts, and at AstraZeneca plc., where he led clinical development worldwide. He also currently serves on the board of directors of Phathom Pharmaceuticals, Inc., a late-stage biopharmaceutical company.

Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. the company believe Mr. Cola?s qualifications to sit on its Board of Directors include his extensive experience working for various pharmaceutical and biotechnology companies. James M. Frates.

Mr. Frates has served as a member of its Board of Directors since May 2014. Since January 2021, Mr. Frates has served as the Chief Financial Officer of Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer?s disease and other neurodegenerative diseases. Mr. Frates previously served as Senior Vice President and Chief Financial Officer of Alkermes plc from September 2011 until January 2021.

From 2007 to 2011, Mr. Frates served as Senior Vice President and Chief Financial Officer of Alkermes, Inc. From 1998 to 2007, Mr. Frates served as Vice President, Chief Financial Officer and Treasurer of Alkermes, Inc. From 1992 to 1994 and 1996 to 1998, he was employed at Robertson, Stephens & Company, most recently as a Vice President in Investment Banking. Prior to that time, he was employed at Morgan Stanley & Co. Mr. Frates earned an A.B. in government from Harvard College and an M.B.A. from Harvard Business School.

The company believe Mr. Frates? qualifications to sit on its Board of Directors include his leadership experience, financial expertise, business judgment and industry knowledge. Jessica J. Federer.

Ms. Federer has served as a member of its Board of Directors since March 2023. Ms. Federer has served as a senior external advisor for McKinsey & Company since January 2024. She previously served as a Partner at Boston Millennia Partners, an investment fund focused on health technology companies, from May 2017 to September 2022.

Ms. Federer also served as Chief Digital Officer at Bayer A.G. from October 2014 to January 2017, and in other leadership roles in regulatory affairs, market access, communications, and public affairs at Bayer A.G. beginning in 2008. She has served on the board of Aspivix SA, a private medical device company based in Switzerland, since December 2023, and as a board member of Pluto Health, a private health tech company, since September 2022. She has also served as an investment advisory board member of the Blavatnik Fund at Yale Ventures, since August 2023; a board member of Angelini Ventures, based out of Rome, Italy, since April 2022; and as a member of the Yale Institutional Review Board for oncology since December 2021.

Ms. Federer served on the United Nations International Telecommunication Union (ITU) advisory board from July 2016 to July 2018. She began her public health career as an analyst at the Agency for Healthcare Research and Quality in the U.S. Department of Health and Human Services. Ms. Federer received a B.S. from the George Washington University and a M.P.H. from Yale University.

The company believe Ms. Federer?s qualifications to sit on its Board of Directors include her extensive experience and leadership in the life sciences industry and track record of using technology to help improve access and care.